W-54011 is a potent, specific, and orally active CD88 (C5a receptor) antagonist.

Danicopan is selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. It has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

EG00229 is the first small molecule inhibitor of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 μM(125I-VEGF binding to PAE/NRP1 cells).

SB 290157 Trifluoroacetate is the trifluoroacetate form of SB 290157. SB 290157 is a competitive and selective C3aR (anaphylatoxin C3a receptor) antagonist. It blocked C3a-induced C3aR internalization in a concentration-dependent manner and C3a-induced Ca(2+) mobilization in RBL-C3aR cells and human neutrophils with IC(50)s of 27.7 and 28 nM, respectively.

PMX 53 is a potent C5a receptor antagonist.

NDT 9513727 is negative allosteric modulator (NAM) of C5a receptor (C5aR) with IC50 of 11.6 nM for human C5aR.

BCX 1470 methanesulfonate inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM), 3.4- and 200-fold better, respectively, than that of trypsin.

AMY 101 is a peptidic central complement component C3 inhibitor with Kd value of 0.5nM. It is now in phase 2 study of Gingivitis, Periodontitis and SARS-CoV-2 acute respiratory disease.

JR14a is a novel potent and selective antagonist of human Complement C3a receptor.